Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peripheral Artery Disease IV: Nursing Management01:26

Peripheral Artery Disease IV: Nursing Management

594
 The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
594
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

651
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
651

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of Sustained Disease Control With Nipocalimab Versus Placebo in the Phase 3 Vivacity-MG3 Study.

European journal of neurology·2026
Same author

Stiff person syndrome: an overview.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same author

Letter to the Editor regarding "Cranial neuropathy during severe acute respiratory syndrome coronavirus 2 infection: a case report".

Journal of medical case reports·2026
Same author

A novel case of compound heterozygous GFPT1 congenital myasthenic syndrome with a coexisting heterozygous DYSF mutation: clinical and pathological insights.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same author

Verdiperstat in Amyotrophic Lateral Sclerosis: Results From the Randomized HEALEY ALS Platform Trial.

JAMA neurology·2025
Same author

Pridopidine in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial.

JAMA·2025

Related Experiment Video

Updated: Mar 26, 2026

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
07:30

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments

Published on: November 9, 2017

10.2K

Paraproteinemic neuropathy: a practical review.

Richard A Rison1, Said R Beydoun2

  • 1University of Southern California, Keck School of Medicine, Los Angeles County Medical Center, Medical Director PIH Health-Whittier Stroke Program, Neurology Consultants Medical Group, 12401 Washington Blvd., Whittier, CA, 90602, USA. rison@usc.edu.

BMC Neurology
|January 30, 2016
PubMed
Summary

Paraproteinemic neuropathies involve excess immunoglobulins from abnormal B-cells. This review offers a practical guide for diagnosing and managing these diverse neurological conditions.

More Related Videos

Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1
09:39

Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1

Published on: February 13, 2018

10.2K
In Vivo Electrophysiological Measurement of the Rat Ulnar Nerve with Axonal Excitability Testing
04:56

In Vivo Electrophysiological Measurement of the Rat Ulnar Nerve with Axonal Excitability Testing

Published on: February 6, 2018

10.2K

Related Experiment Videos

Last Updated: Mar 26, 2026

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
07:30

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments

Published on: November 9, 2017

10.2K
Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1
09:39

Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1

Published on: February 13, 2018

10.2K
In Vivo Electrophysiological Measurement of the Rat Ulnar Nerve with Axonal Excitability Testing
04:56

In Vivo Electrophysiological Measurement of the Rat Ulnar Nerve with Axonal Excitability Testing

Published on: February 6, 2018

10.2K

Area of Science:

  • Neurology
  • Immunology
  • Hematology

Background:

  • Paraproteinemic neuropathies are a diverse group of nerve disorders.
  • They are characterized by the presence of homogeneous immunoglobulins in the serum.
  • These immunoglobulins result from abnormal B-lymphocyte or plasma cell proliferation, potentially linked to hematologic malignancy.

Purpose of the Study:

  • To provide a clinically practical approach to the diagnosis and management of paraproteinemic neuropathies.
  • To synthesize current knowledge given the limited availability of high-level evidence.
  • To guide clinicians in managing patients with these complex conditions.

Main Methods:

  • Review of clinical experience and uncontrolled studies.
  • Synthesis of data to inform management recommendations.
  • Development of a practical diagnostic and management strategy.

Main Results:

  • Paraproteinemic neuropathies are heterogeneous, with most cases classified as monoclonal gammopathy of undetermined significance.
  • Treatment strategies depend on the underlying cause, with targeted therapy for malignancy-associated cases.
  • Clinical expertise and smaller studies form the basis for current management guidelines.

Conclusions:

  • A structured approach to diagnosis and management is crucial for paraproteinemic neuropathies.
  • Treatment should be tailored to the individual patient's clinical context and the specific paraprotein.
  • Further research, including randomized controlled trials, is needed to refine treatment protocols.